Phase I adoptive cellular therapy trial with ex-vivo stimulated autologous CD8+ T-cells against multiple targets (ACTolog® IMA101) in patients with relapsed and/or refractory solid cancers
Tsimberidou, A.-M., Ma, H., Stewart, C., Schoor, O., Maurer, D., Mendrzyk, R., Satelli, A., Fritsche, J., Stephens, G., Mohamed, A., Hwu, P., Yee, C., Reinhardt, C., Weinschenk, T., Gharpure, K., Stungis, A., Vining, D.J., Singh, H., Walter, S., Andersson, B.S.
Published in Annals of oncology (01.10.2018)
Published in Annals of oncology (01.10.2018)
Get full text
Journal Article
1155PPhase I adoptive cellular therapy trial with ex-vivo stimulated autologous CD8+ T-cells against multiple targets (ACTolog® IMA101) in patients with relapsed and/or refractory solid cancers
Tsimberidou, A-M, Ma, H, Stewart, C, Schoor, O, Maurer, D, Mendrzyk, R, Satelli, A, Fritsche, J, Stephens, G, Mohamed, A, Hwu, P, Yee, C, Reinhardt, C, Weinschenk, T, Gharpure, K, Stungis, A, Vining, D J, Singh, H, Walter, S, Andersson, B S
Published in Annals of oncology (01.10.2018)
Published in Annals of oncology (01.10.2018)
Get full text
Journal Article